Moderate

Hypertension in chronic kidney disease

CKD-HTN · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Hypertension is both a cause and consequence of CKD and a key driver of progression and cardiovascular death. Management centres on a lower BP target, RAAS blockade for albuminuria, sodium restriction and stepwise add-on therapy.

Red flags

  • Accelerated/malignant hypertension with retinal haemorrhages or encephalopathy
  • Flash pulmonary oedema suggesting bilateral renal artery stenosis
  • Severe hyperkalaemia with ECG changes
  • Rapidly worsening renal function on treatment
  • BP >180/120 with acute end-organ damage (hypertensive emergency)

Assessment

Differential diagnosis

  • Primary hypertension with CKD
  • Renovascular hypertension / renal artery stenosis
  • Primary hyperaldosteronism
  • Volume overload (ESKD/dialysis)
  • Glomerular disease with nephrotic-range proteinuria
  • White-coat / masked hypertension

Investigations

  • Standardised clinic BP plus home or ambulatory BP monitoring
  • U&E, eGFR and potassium
  • Urine ACR
  • Aldosterone:renin ratio if resistant/hypokalaemic
  • Renal ultrasound +/- duplex if renovascular disease suspected
  • ECG/echo for end-organ damage

Management

  • Confirm sustained hypertension with out-of-office readings (home/ABPM) to exclude white-coat effect
  • Set target: generally <130/80 mmHg where tolerated, individualised for frailty and orthostasis
  • Reinforce sodium restriction (<2 g sodium/day), weight loss, alcohol moderation and exercise
  • First-line pharmacotherapy is an ACE inhibitor or ARB, especially with albuminuria; uptitrate to max tolerated
  • Recheck U&E/potassium 1-2 weeks after starting or escalating RAAS blockade
  • Add a dihydropyridine calcium-channel blocker and/or a thiazide-like diuretic as second/third agents
  • Use a loop diuretic instead of thiazide when eGFR <30 mL/min or volume overloaded
  • For resistant hypertension confirmed on 3 agents including a diuretic, add spironolactone if potassium and eGFR permit
  • Monitor for and manage hyperkalaemia; consider potassium binders to enable RAAS/MRA therapy
  • Screen for secondary causes (aldosteronism, renovascular disease) in resistant or hypokalaemic cases
  • Assess adherence and remove BP-raising agents (NSAIDs, decongestants)
  • Review BP, renal function and potassium at regular intervals and after each change

Drugs & doses

Ramipril 2.5-10 mg PO daily OR losartan 50-100 mg PO daily
Amlodipine 5-10 mg PO once daily
Indapamide 2.5 mg PO once daily (eGFR >30) or furosemide 20-80 mg PO daily (eGFR <30 / overload)
Spironolactone 25 mg PO daily for resistant HTN (if K+ <=4.5, eGFR >45)
Doxazosin MR 4-8 mg PO daily (add-on)
Patiromer 8.4 g PO daily or sodium zirconium cyclosilicate 5-10 g PO daily for hyperkalaemia enabling RAAS therapy

Disposition

Primary care/CKD clinic. Nephrology or hypertension specialist for resistant or secondary hypertension. Emergency assessment for hypertensive emergency/malignant hypertension.

Complications & pitfalls

  • Accelerated CKD progression
  • Left ventricular hypertrophy and heart failure
  • Stroke and cardiovascular events
  • Hyperkalaemia from RAAS/MRA therapy
  • Hypotension and falls, especially in frail/elderly
  • Retinopathy

Exam pearls

  • ACE inhibitor/ARB is first-line when albuminuria is present
  • Switch thiazide to loop diuretic when eGFR <30
  • Confirm resistance with adherence check and out-of-office readings before escalating
  • Potassium binders can enable continuation of prognostically important RAAS/MRA therapy
  • NSAIDs and decongestants are common hidden causes of resistant hypertension

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.